Cargando…

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial

IMPORTANCE: Prostate radiotherapy (RT) improves survival in men with low-burden metastatic prostate cancer. However, owing to the dichotomized nature of metastatic burden criteria, it is not clear how this benefit varies with bone metastasis counts and metastatic site. OBJECTIVE: To evaluate the ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Adnan, Hoyle, Alex, Haran, Áine M., Brawley, Christopher D., Cook, Adrian, Amos, Claire, Calvert, Joanna, Douis, Hassan, Mason, Malcolm D., Dearnaley, David, Attard, Gerhardt, Gillessen, Silke, Parmar, Mahesh K. B., Parker, Christopher C., Sydes, Matthew R., James, Nicholas D., Clarke, Noel W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893550/ https://www.ncbi.nlm.nih.gov/pubmed/33599706 http://dx.doi.org/10.1001/jamaoncol.2020.7857

Ejemplares similares

The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE’s “M1|RT Comparison”
por: Ali, Adnan, et al.
Publicado: (2020)

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
por: Parker, Christopher C, et al.
Publicado: (2018)

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial
por: Parker, Chris C., et al.
Publicado: (2022)

Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials
por: Dearnaley, David P, et al.
Publicado: (2009)

Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data
por: Clarke, Caroline S., et al.
Publicado: (2022)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial
por: Parry, Marina A., et al.
Publicado: (2023)

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
por: Clarke, N W, et al.
Publicado: (2019)

Accumulation of copy number alterations and clinical progression across advanced prostate cancer
por: Grist, Emily, et al.
Publicado: (2022)

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
por: Burdett, Sarah, et al.
Publicado: (2019)

Consensus on the Screening, Staging, Treatment, and Surveillance of Localized, Recurrent, and Metastatic Prostate Cancer: The First Global Prostate Cancer Consensus Conference for Developing Countries
por: Maluf, Fernando Cotait, et al.
Publicado: (2021)

Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992–2003
por: Clarke, N.W., et al.
Publicado: (2020)

Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis
por: Rydzewska, Larysa H.M., et al.
Publicado: (2017)

Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
por: Attard, Gerhardt, et al.
Publicado: (2022)

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
por: Vale, Claire L, et al.
Publicado: (2016)

Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial
por: Sydes, Matthew R, et al.
Publicado: (2009)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
por: Yekedüz, Emre, et al.
Publicado: (2023)

Metastatic prostate cancer masquerading as lymphangioma circumscriptum
por: Gerhardt, Caroline A., et al.
Publicado: (2022)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Genome-wide plasma DNA methylation features of metastatic prostate cancer
por: Wu, Anjui, et al.
Publicado: (2020)

Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase II trial
por: Morant, R, et al.
Publicado: (2004)

Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial
por: James, Nicholas D, et al.
Publicado: (2022)

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
por: Salvi, Samanta, et al.
Publicado: (2016)

Radioisotopes in management of metastatic prostate cancer
por: Raval, Amar, et al.
Publicado: (2016)

Tuberculous prostatitis mimicking metastatic prostate cancer
por: Aslan, Serdar, et al.
Publicado: (2022)

Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer
por: Conteduca, Vincenza, et al.
Publicado: (2020)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Severe Hypocalcemia due to Denosumab in Metastatic Prostate Cancer
por: Muqeet Adnan, Mohammed, et al.
Publicado: (2014)

Sequence of treatment in locally advanced and metastatic renal cell carcinoma
por: Fischer, Stefanie, et al.
Publicado: (2015)

The dedifferentiation of metastatic prostate carcinoma.
por: Brawn, P. N., et al.
Publicado: (1989)

Immunotherapy in metastatic prostate cancer
por: Slovin, Susan F.
Publicado: (2016)

Metastatic Prostate Cancer of Hand
por: Nagano, Akihito, et al.
Publicado: (2016)

Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2021)

The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
por: Fosså, S. D., et al.
Publicado: (1992)

Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer
por: Inaba, Koji, et al.
Publicado: (2021)

Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5‐year follow‐up results from the STAMPEDE randomised trial (NCT00268476)
por: James, Nicholas D., et al.
Publicado: (2022)

Local therapy in patients with metastatic prostate cancer: a new standard of care?
por: Harper, Benjamin, et al.
Publicado: (2019)

Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer
por: South, Annabelle, et al.
Publicado: (2016)

Hepatic Dysfunction as a Paraneoplastic Manifestation of Metastatic Prostate Adenocarcinoma
por: Kato, David, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_t6rrjpu1essigf043jbqtvv68s